Alnylam Pharmaceuticals (ALNY) Receivables (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Receivables data on file, last reported at $884.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 111.46% year-over-year to $884.0 million; the trailing twelve-month figure through Mar 2026 stood at $884.0 million (up 111.46% YoY), and the FY2025 full-year result was $777.6 million, up 91.85% from the prior year.
• Receivables for Q1 2026 stood at $884.0 million, up from $777.6 million in the prior quarter.
• Across five years, Receivables topped out at $964.8 million in Q3 2025 and bottomed at $9.1 million in Q2 2022.
• The 5-year median for Receivables is $321.4 million (2024), against an average of $350.2 million.
• The widest annual swing landed in 2022, when Receivables plunged 98.6%; it then jumped 2331.51% in 2023.
• A 5-year view of Receivables shows it stood at $32.3 million in 2022, then jumped by 207.88% to $99.6 million in 2023, then jumped by 307.03% to $405.3 million in 2024, then jumped by 91.85% to $777.6 million in 2025, then advanced by 13.68% to $884.0 million in 2026.
• The last three Receivables figures came in at $884.0 million (Q1 2026), $777.6 million (Q4 2025), and $964.8 million (Q3 2025), per Business Quant data.

Peer Comparison